Intravenous immunoglobulin for pembrolizumab‐induced bullous pemphigoid‐like eruption: A case report
Authors:
Open Access
- 31 October 2022
- journal article
- letter
- Published by Hindawi Limited in Dermatologic Therapy
- Vol. 35 (12) , e15948
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysisJournal of the American Academy of Dermatology, 2022
- Retrospective Analysis of Checkpoint Inhibitor Therapy-Associated Cases of Bullous Pemphigoid From Six German Dermatology CentersFrontiers in Immunology, 2021
- Neutropenia resulting from high-dose intravenous immunoglobulin in dermatological patientsJDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2020
- Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic ReviewFrontiers in Immunology, 2020
- Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibitionJournal for ImmunoTherapy of Cancer, 2019
- The growth capacity of hematopoietic progenitor cells in severe neutropenia induced by famotidineAnnals of Hematology, 1992